Background The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear. We aimed to undertake an integrated analysis of a complete human genome in a clinical context.
Introduction
Technological advance has greatly reduced the cost of genetic information. However, the explanatory power and path to clinical translation of risk estimates for common variants reported in genome-wide association studies remain unclear. Much of the reason lies in the presence of rare and structural genetic variation. Since we are now able to rapidly and inexpensively sequence complete genomes, [1] [2] [3] [4] [5] comprehensive genetic risk assessment and individ ualisation of treatment might be possible. 6 How ever, present analytical methods are insuffi cient to make genetic data accessible in a clinical context, and the clinical usefulness of these data for individual patients has not been formally assessed. We aimed to undertake an inte grated analysis of a complete human genome in a clinical context.
Methods

Patient
A patient with a family history of vascular disease and early sudden death was assessed at Stanford's Center for Inherited Cardiovascular Disease by a cardiologist (EAA) and a board-certifi ed genetic counsellor (KEO). We took the patient's medical history and he was clinically assessed. A four-generation pedigree was drawn. In view of his family history, he underwent electrocardiography, an echocardiogram, and a cardiopulmonary exercise test.
Genome analysis
Technical details of genome sequencing for this patient have been described previously. 7 In brief, genomic DNA was purifi ed from 2 mL of whole blood and sequenced with a Heliscope (Helicos BioSciences, Cambridge, MA, USA) genome sequencer. We mapped sequence data to the National Center for Biotechnology Information reference human genome build 36 using the open-source aligner IndexDP (Helicos BioSciences, Cambridge, MA, USA). 7 Base calling was done with the UMKA algorithm.
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A subset of single nucleotide polymorphism calls were independently validated with the Illumina BeadArray (San Diego, CA, USA) and all variants reported here and discussed with the patient were validated with Sanger sequencing. A subset of copy number variation calls were independently validated with digital PCR.
Disease and risk analysis
Analysis focused on four areas: (i) variants associated with genes for mendelian disease; (ii) novel mutations; (iii) variants known to modulate response to pharma cotherapy; and (iv) single nucleotide polymorphisms previously associated with complex disease. Database queries, biophysical prediction algorithms, and analyses of non-coding regions were used to screen for rare and novel variants in the genome. We examined diseasespecifi c mutation databases, the human genome mutation database, and Online Mendelian Inheritance in Man to identify genes and mutations with known associations to monogenic diseases. We applied prediction algorithms to weight the likelihood of variant pathogenicity on the basis of allele frequency, conservation, and protein domain disruption. Addi tionally, we developed algorithms to index variants aff ecting or creating start sites, stop sites, splice sites, and microRNAs (fi gure 1; webappendix p 2).
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The Pharmacogenomics Knowledge Base (PharmGKB) 14 contains data for 2500 variants, of which 650 refer specifi cally to drug-response phenotypes. PharmGKB curators examined these 650 annotations in the context of the patient's genotype. Key variants were identifi ed on the basis of the relevance of the phenotype in the annotation, the medical and family history, and the study population on which the annotation was based. Since our disease-risk estimation and pharmacogenomic analysis drew on previous reports, we rated the evidence used in one of three categories (webappendix p 2). To integrate common variant genetic risk across a range of human disease, we built a manually curated disease and single-nucleotide-polymorphism database (webappendix p 2). Diseases and phenotypes were mapped to Unifi ed Medical Language System Concept Unique Identifi ers (webappendix p 3). Since strand direction was variably reported between studies, we identifi ed strand direction by comparing with major or minor alleles in the appropriate HapMap population. Odds ratios were available for allele comparisons in most cases (webappendix p 7); however, to generate a medically relevant post-test probability of disease from integrated environmental and genetic risk, we calculated likelihood ratios (LRs) for the most important single nucleotide polymorphism from every haplotype block. Pre-test probability was derived from published sources (webappendix p 16) and the LR was applied to the pre-test odds of disease, which were calculated from ageappropriate and sex-appropriate population prevalence. Investigators did not always provide frequency data for genotype that allowed calculation of the LR.
The study was reviewed by the institutional review board of Stanford University and the patient gave written consent. The patient received education and counselling before signing the consent form and throughout testing and follow-up.
Role of the funding source
The study sponsors had no role in the design, data collection, data analysis, data interpretation, or writing of the report. EAA had full access to all data in the study and fi nal responsibility for the decision to submit for publication.
Results
The patient was a 40-year-old man who presented with a family history of coronary artery disease and sudden death. His medical history was not clinically signifi cant and the patient exercised regularly without symptoms. He was taking no prescribed medications and appeared well. Clinical characteristics were within normal limits (table 1) . Electrocardiography showed sinus rhythm, normal axis, and high praecordial voltage with early repolarisation. An echocardiogram revealed normal right and left ventricular size, systolic, diastolic, and valvular function. There were no wall motion abnormalities during maximum exercise and 1·5 mm ST depression was upsloping. Maximum oxygen uptake was 50 mL/kg per min. A four-generation family pedigree (fi gure 2) showed atherosclerotic vascular disease with several manifestations and prominent osteoarthritis. The patient's fi rst cousin once removed (IV-1) died suddenly of an unknown cause.
Sequencing of genomic DNA resulted in an output of 148 GB of raw sequence, with an average read length of 33 bases. 7 Base calling detected 2·6 million single nucleotide polymorphisms and 752 copy number variations.
An important benefi t of sequencing compared with DNA chip-based methods of genotyping is the identifi cation of rare or novel variants. We searched for evidence of rare or novel variants that would predispose the patient or his family to disease ( 24 The identifi ed DSP variant, encoding an arginine-to-histidine change to aminoacid 1838 of the desmoplakin protein, is entirely novel. Control populations from clinical testing laboratories (more than 1000 total chromosomes) did not contain either the DSP or TMEM43 variants.
Analysis of the patient's genome revealed three novel and potentially damaging variants in two related genes that were previously associated with development of haemochromatosis. Subsequent to these fi ndings, detailed review of personal and family history did not identify a history of haemochromatosis in the patient or family members. Echocardiogram results and liver function tests did not show evidence of the disease. Justifi cation for continued surveillance and testing with serum iron studies was explored with the patient. Additionally, the patient had a novel stop mutation in a gene implicated in hyperparathyroidism and parathyroid SNP=single nucleotide polymorphism. HMG-CoA=3-hydroxy-3-methylglutaryl-coenzyme A. tumours. This variant might increase probability of future development of hyperparathyroidism or parathyroid tumours through a loss-of-heterozygosity mechanism. Consistent with a variant in a gene previously associated with osteoarthritis, there was a family history of osteoarthritis and the patient reported chronic knee pain without a formal diagnosis. We noted 63 clinically relevant previously described pharmacogenomic variants (table 3, table 4 ; webappendix p 11) [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] and six novel, non-conservative, aminoacidchanging single nucleotide polymorphisms in genes that are important for drug response. There was a heterozygous null mutation in CYP2C19, the gene product of which is important for metabolism of many drugs, including proton-pump inhibitors, antiepileptic drugs, and the antiplatelet agent clopidogrel. Notably, the rate of cardiovascular events is raised in patients with CYP2C19 loss-of-function mutations who take clopidogrel. 46 Additionally, the patient had two types of distinct genetic variations related to decreased maintenance dosing of warfarin. The patient had the single most important variant in VKORC1 associated with a low maintenance dose, 47 and was homozygous for a CYP4F2 single nucleotide polymorphism that is associated with reduced dosing. 48 Thus, if prescription of warfarin became necessary, loading could be individually tailored for this patient, with lowered expected doses. The patient had several variants that are associated with good response to statins (including reduced risk of myopathy) and one variant suggesting that he might need a raised dose to achieve a good response. Finally, the patient was wild type (with no copy number variations) for genes for important drug-metabolising enzymes (CYP2D6, CYP2C9, and CYP3A4) aff ecting hundreds of drug responses.
Although genome-wide association studies have provided strong association of many common variants with disease, integration of these small odds ratios in the context of the individual patient remains challenging. In particular, additive or multiplicative models of even strongly associated single nucleotide polymorphisms can add little to the classifi ed status of the patient. 49, 50 Furthermore, these approaches take no account of previous probability of disease. To counter some of these concerns, we adopted established methods from within evidence-based medicine that have rarely been applied to clinical genetics. We estimated pre-test probabilities from referenced sources for 121 diseases (webappendix p 7). Of the 55 diseases for which we could estimate a post-test probability, genetic risk was consistently increased (LR >2) for eight diseases and decreased (<0·5) for seven diseases (fi gure 3). The advantage of plotting pre-test and post-test probabilities is shown by several examples-eg, although the patient has increased genetic risk for Graves' disease, because the pretest probability of this disease is very low, post-test probability also remains low. Conversely, although the patient has a low genetic contribution to his risk for prostate cancer, his estimated pre-test probability is high, resulting in a high overall post-test probability.
Raised genetic risk did not always translate into high post-test probability. Post-test probabilities that were an order of magnitude higher or lower than pre-test probabilities were rare. Any decision towards acting on these predictions will necessarily be a function of the post-test probability threshold for action (eg, the post-test probability of type 2 diabetes), the consequences of action (eg, regular testing for fasting blood sugar), and the usefulness and eff ectiveness of action.
Figure 3: Clinical risk incorporating genetic-risk estimates for major diseases
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Gene
polymorphism has been associated with a low number of kringle IV-2 (KIV-2) domain repeats in LPA, high lipoprotein(a) concentrations, and adverse cardiovascular events. 52, 53 Because of the technical limitations of short-read sequencing, a precise estimate of the number of KIV-2 domains in the patient's genome sequence was not established.
We placed disease-associated genetic risk into the context of environmental and behavioural modifi ers, as well as predisposing disorders (fi gure 5). Diseases that might be independently associated with low genetic risk (eg, abdominal aortic aneurysm) were assessed in the context of others that could be causally related but for which genetic risk might be higher (eg, obesity, which predisposes to type 2 diabetes and hypertension). Thus, overall risk could then be assessed with both direct and conditionally dependent information because they were shown together in the circuit. For example, we predicted a reduced risk probability for hypertension of 16·8% (LR 0·81) relative to the general population; however, the patient had a substantially raised genetic risk of obesity (LR 6·28), imparting a high post-test risk of 56·1% for a predisposing risk factor for hypertension. Furthermore, hypertension is associated with several modifi able environmental factors aff ecting risk either directly (eg, sodium intake) or conditionally by association with another node in the circuit (eg, antipsychotic drugs). Although no methods exist for statistical integration of such conditionally dependent risks, interpretation of fi ndings in the context of the causal circuit diagram allows assessment of the combined eff ect of environmental and genetic risk for every individual.
During genetic counselling, we discussed the possibility that clinical assessment incorporating a personal genome might uncover high risk of a serious disease, including some for which there is no treatment. Additionally, we described the reproductive implications of heterozygous status for autosomal recessive diseases such as cystic fi brosis, which might not be predictable from family history (table 2, fi gure 1). We also warned of increases or decreases in genetic risk for common diseases. We noted that most of the sequence information is diffi cult to interpret, and discussed error rates and validation processes. Additionally, we discussed that risk alleles might be discovered that have reproductive or familial importance rather than personal importance (such as those for breast or ovarian cancer). We addressed the possibility of dis crim ination on the basis of genetics. Although a specialised physician can provide information for a patient seeking a genetic test for a specifi c disease, patients with whole genome sequence data need inform ation about more diseases with a wide clinical range (table 2) . For this reason, we off ered extended access to clinical geneticists, genetic counsellors, and clinical lab directors to interpret the information we presented.
Discussion
We provide an approach to comprehensive analysis of a human genome in a defi ned clinical context. We assessed whole-genome genetic risk, focusing on variants in genes that are associated with mendelian disease, novel and rare variants across the genome, and variants of pharmacogenomic importance. Additionally, we developed an approach to the integration of disease risk across several common polymorphisms. Although the methods that we used are nascent, the results provide proof of principle that clinically meaningful information can be derived about disease risk and response to drugs in patients with whole genome sequence data.
Prominent aspects of the patient's family history (fi gure 1) were diagnosis of arrythmogenic right ventricular dysplasia or cardiomyopathy in his fi rst cousin (III-3) and the sudden death of his fi rst cousin once removed (IV-1). Our patient shares 12·5% of his genetic information with his fi rst cousin and 6·25% with that relative's son and, although a diagnostic workup would involve targeted sequencing of DNA from these individuals, our analysis uncovered several variants in genes with potential explanatory value. Most were common variants. One gene variant (in MYBPC3) was previously associated with hypertrophic cardiomyopathy, but seems to be a common variant; this exemplifi es the limitations of present variant databases. Two rare variants in genes (TMEM43, DSP) previously associated with arrythmogenic right ventricular dysplasia or cardiomyopathy were novel.
Our patient reported a prominent family history of vascular disease including aortic aneurysm and coronary artery disease (fi gure 2; individuals II-1, II-2, I-1, I-2). During estimation of the risk of coronary artery disease, we integrated the most replicated risk associations, likelihood ratio projections from published work, and a known variant in LPA that might not have been identifi ed with chip-based genotyping. According to adult treatment panel III guidelines, 54 our patient does not currently have major risk factors for coronary artery disease and would need an LDL concentration higher than 4·9 mmol/L to qualify for lipid-lowering therapy in the USA. However, he is borderline for three major risk factors (one of which is age) and any two of these would lower the threshold for treatment to 4·1 mmol/L (his measured LDL concentration was 4·0 mmol/L). Although no standards yet exist for the incorporation of global genetic risk in cardiovascular risk assessment, physicians are accustomed to incorporating many sources of information in clinical decision making. In this case, the patient's physician considered lifetime genetic risk and likely response to therapy when making the clinical decision to recommend a lipid-lowering drug. The patient's genome includes variants ( and his patient about the threshold for primary prevention with aspirin therapy. In view of a predisposition to coronary artery disease and other diseases on which risk is conditionally dependent (fi gure 5), understanding of the patient's potential response to clopidogrel and warfarin might be important for individualisation of future medical therapy. The patient is at risk of clopidogrel resistance as a result of his CYP2C19 loss-of-function mutation, and his physician might recommend either an increased dose of clopidogrel in the event of future use, or consideration of new agents with alternative metabolism. By contrast, should the patient develop an indication for warfarin, his genotype at the VKORC1 and CYP4F2 loci suggests that he should take reduced initial doses of warfarin.
By contrast, our patient did not report a family history of haemochromatosis or parathyroid tumours, yet has some genetic risk for these disorders. In consideration of future screening studies, integrated clinical and genetic risks were assessed.
Important limitations remain in our ability to comprehensively integrate genetic information into clinical care. For example, a comprehensive database of rare mutations is needed. Since risk estimates change as studies are completed, a continually updated pipeline is necessary. There are imperfections in all human genomes published to date-false positive and false negative SNP calls, incomplete measurement of structural variation, and little direct haplotype data. Finally, gene-environment interactions are challenging to quantify and have been little studied.
As whole-genome sequencing becomes increasingly widespread, availability of genomic information will no longer be the limiting factor in application of genetics to clinical medicine. Development of methods integrating genetic and clinical data will assist clinical decision making and represent a large step towards individualised medicine. The transition to a new era of genomeinformed medical care will need a team approach incorporating medical and genetics professionals, ethicists, and health-care delivery organisations.
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